MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

03 Sep 2015 Evaluate

Glenmark Pharmaceuticals has informed about a Press Release dated September 03, 2015 titled ‘Glenmark’s novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe’.

The above information is a part of company’s filings submitted to BSE.


 

Peers
Company Name CMP
Sun Pharma. Inds. 1758.30
Dr. Reddys Labs. 1179.20
Cipla 1299.20
Lupin 1950.30
Zydus Lifesciences 1110.15
View more..